SCHEDULE: Major Investor Group Sells Werewolf Therapeutics Shares

An investor group led by MPM BioImpact and its affiliates reported open market sales of Werewolf Therapeutics common stock, reducing their collective beneficial ownership.

Summary

• MPM BioImpact and affiliated entities and individuals filed an Amendment No. 2 to their Schedule 13D, reporting open market sales of Werewolf Therapeutics, Inc. common stock.
• The sales occurred between November 4, 2025, and November 17, 2025, with average sale prices ranging from $0.93 to $1.22 per share.
• A total of 640,730 shares were sold by the reporting persons during this period.
• Ansbert Gadicke, a key individual in the group, now beneficially owns 5,481,539 shares, representing 11.3% of the outstanding common stock.
• Luke Evnin beneficially owns 3,515,880 shares, representing 7.2% of the outstanding common stock.
• Todd Foley beneficially owns 2,617,924 shares, representing 5.4% of the outstanding common stock.
• MPM BioVentures 2014 LLC, a key entity, beneficially owns 2,617,924 shares, representing 5.4% of the outstanding common stock.
• The percentage of common stock beneficially owned is calculated based on 48,540,200 shares outstanding as of October 29, 2025.

Sentiment

Score: 3

Explanation: The filing reports substantial open market sales of Werewolf Therapeutics common stock by a group of significant beneficial owners, including key individuals associated with MPM BioImpact. This reduction in stake, particularly over a period of declining prices, typically signals a lack of confidence or a strategic exit, which is a negative indicator for the company's stock.

Negatives

• Significant open market sales by a major investor group, including key individuals like Ansbert Gadicke, Luke Evnin, and Todd Foley, totaling 640,730 shares.
• The sales occurred over several days, with average prices declining from $1.22 to $0.93 per share.
• The reduction in beneficial ownership by a significant investor group could signal reduced confidence or a strategic shift regarding Werewolf Therapeutics.

Risks

• Increased selling pressure on Werewolf Therapeutics' stock due to ongoing or potential future sales by this investor group.
• Potential negative market perception stemming from a major investor group reducing its stake, which could impact investor confidence.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Werewolf Therapeutics, Inc. It solely reports past transactions by a group of beneficial owners.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major investor group in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape, but significant sales by a venture capital group in the biotech sector can sometimes reflect a shift in investment strategy or a response to company-specific developments not detailed in this filing.

Comparison to Industry Standards

• Not applicable. This filing reports specific share transactions by a particular investor group and does not contain company performance data or operational results that can be benchmarked against industry standards or comparable companies.

Related Party Transactions

• The filing details open market sales of common stock by a group of affiliated investment funds and individuals who are significant beneficial owners of Werewolf Therapeutics. These transactions involve parties with a significant relationship to the issuer.

Stakeholder Impact

• Shareholders: Existing shareholders may experience increased selling pressure and a potential decline in share price due to the significant sales by a major investor group. The sales could also erode investor confidence.
• Company Management: May face questions regarding the reasons for the major investor group's divestment and its implications for future capital raising or strategic direction.

Key Dates

Recommendation

The significant open market sales by a major investor group, including key individuals, over a period of declining prices, suggest a lack of conviction or a strategic exit. This action by informed investors typically signals potential headwinds or a perceived overvaluation, making a 'sell' recommendation prudent for existing holders and caution for potential buyers.

Keywords

Werewolf Therapeutics, WOLF, SEC filing, Schedule 13D, beneficial ownership, stock sales, MPM BioImpact, Ansbert Gadicke, Luke Evnin, Todd Foley, biotech, oncology